Cidara Therapeutics Inc
NASDAQ:CDTX

Watchlist Manager
Cidara Therapeutics Inc Logo
Cidara Therapeutics Inc
NASDAQ:CDTX
Watchlist
Price: 13.9 USD Market Closed
Market Cap: 97.8m USD
Have any thoughts about
Cidara Therapeutics Inc?
Write Note

Intrinsic Value

CDTX's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one CDTX stock under the Base Case scenario is 19.79 USD. Compared to the current market price of 13.9 USD, Cidara Therapeutics Inc is Undervalued by 30%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

CDTX Intrinsic Value
19.79 USD
Undervaluation 30%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Cidara Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for CDTX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about CDTX?
Bearish
Neutral
Bullish

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Cidara Therapeutics Inc

Provide an overview of the primary business activities
of Cidara Therapeutics Inc.

What unique competitive advantages
does Cidara Therapeutics Inc hold over its rivals?

What risks and challenges
does Cidara Therapeutics Inc face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Cidara Therapeutics Inc.

Provide P/S
for Cidara Therapeutics Inc.

Provide P/E
for Cidara Therapeutics Inc.

Provide P/OCF
for Cidara Therapeutics Inc.

Provide P/FCFE
for Cidara Therapeutics Inc.

Provide P/B
for Cidara Therapeutics Inc.

Provide EV/S
for Cidara Therapeutics Inc.

Provide EV/GP
for Cidara Therapeutics Inc.

Provide EV/EBITDA
for Cidara Therapeutics Inc.

Provide EV/EBIT
for Cidara Therapeutics Inc.

Provide EV/OCF
for Cidara Therapeutics Inc.

Provide EV/FCFF
for Cidara Therapeutics Inc.

Provide EV/IC
for Cidara Therapeutics Inc.

Show me price targets
for Cidara Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Cidara Therapeutics Inc?

How accurate were the past Revenue estimates
for Cidara Therapeutics Inc?

What are the Net Income projections
for Cidara Therapeutics Inc?

How accurate were the past Net Income estimates
for Cidara Therapeutics Inc?

What are the EPS projections
for Cidara Therapeutics Inc?

How accurate were the past EPS estimates
for Cidara Therapeutics Inc?

What are the EBIT projections
for Cidara Therapeutics Inc?

How accurate were the past EBIT estimates
for Cidara Therapeutics Inc?

Compare the revenue forecasts
for Cidara Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Cidara Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Cidara Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Cidara Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Cidara Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Cidara Therapeutics Inc with its peers.

Analyze the financial leverage
of Cidara Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Cidara Therapeutics Inc.

Provide ROE
for Cidara Therapeutics Inc.

Provide ROA
for Cidara Therapeutics Inc.

Provide ROIC
for Cidara Therapeutics Inc.

Provide ROCE
for Cidara Therapeutics Inc.

Provide Gross Margin
for Cidara Therapeutics Inc.

Provide Operating Margin
for Cidara Therapeutics Inc.

Provide Net Margin
for Cidara Therapeutics Inc.

Provide FCF Margin
for Cidara Therapeutics Inc.

Show all solvency ratios
for Cidara Therapeutics Inc.

Provide D/E Ratio
for Cidara Therapeutics Inc.

Provide D/A Ratio
for Cidara Therapeutics Inc.

Provide Interest Coverage Ratio
for Cidara Therapeutics Inc.

Provide Altman Z-Score Ratio
for Cidara Therapeutics Inc.

Provide Quick Ratio
for Cidara Therapeutics Inc.

Provide Current Ratio
for Cidara Therapeutics Inc.

Provide Cash Ratio
for Cidara Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Cidara Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Cidara Therapeutics Inc?

What is the current Free Cash Flow
of Cidara Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Cidara Therapeutics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Cidara Therapeutics Inc

Current Assets 168.6m
Cash & Short-Term Investments 164.4m
Receivables 2.3m
Other Current Assets 1.9m
Non-Current Assets 4.8m
PP&E 4.7m
Other Non-Current Assets 104k
Current Liabilities 39.6m
Accounts Payable 2.3m
Accrued Liabilities 37.1m
Other Current Liabilities 265k
Non-Current Liabilities 2.8m
Long-Term Debt 445k
Other Non-Current Liabilities 2.3m
Efficiency

Earnings Waterfall
Cidara Therapeutics Inc

Revenue
39.1m USD
Operating Expenses
-75.5m USD
Operating Income
-36.4m USD
Other Expenses
-78.9m USD
Net Income
-115.3m USD

Free Cash Flow Analysis
Cidara Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

CDTX Profitability Score
Profitability Due Diligence

Cidara Therapeutics Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.

ROE is Increasing
ROIC is Increasing
Negative 3-Years Revenue Growth
Negative 1-Year Revenue Growth
21/100
Profitability
Score

Cidara Therapeutics Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.

CDTX Solvency Score
Solvency Due Diligence

Cidara Therapeutics Inc's solvency score is 67/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Negative Net Debt
Low D/E
67/100
Solvency
Score

Cidara Therapeutics Inc's solvency score is 67/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CDTX Price Targets Summary
Cidara Therapeutics Inc

Wall Street analysts forecast CDTX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CDTX is 30.26 USD with a low forecast of 24.24 USD and a high forecast of 42 USD.

Lowest
Price Target
24.24 USD
74% Upside
Average
Price Target
30.26 USD
118% Upside
Highest
Price Target
42 USD
202% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for CDTX?

Click here to dive deeper.

Dividends

Cidara Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for CDTX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Cidara Therapeutics Inc Logo
Cidara Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

97.8m USD

Dividend Yield

0%

Description

Cidara Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of novel anti-infectives. The company is headquartered in San Diego, California and currently employs 89 full-time employees. The company went IPO on 2015-04-15. The firm is focused on the discovery, development and commercialization of therapeutics designed for the care of patients facing serious fungal or viral infections. The firm's lead product candidate is rezafungin acetate, an intravenous formulation of an echinocandin. Rezafungin is being developed as a once-weekly, high-exposure therapy for the treatment and prevention of serious invasive fungal infections. Rezafungin acetate is in Phase III of chemical trials. Its Cloudbreak antiviral platform consist of pipelines to develop Antiviral Conjugates (AVCs) for the prevention and treatment of influenza and other viral infections, including respiratory syncytial virus (RSV), human immunodeficiency virus (HIV) and the SARS-CoV-2 strains causing COVID-19. The firm's subsidiary includes Cidara Therapeutics United Kingdom Limited and Cidara Therapeutics (Ireland) Limited.

Contact

CALIFORNIA
San Diego
6310 Nancy Ridge Dr Ste 101
+18587526170.0
www.cidara.com

IPO

2015-04-15

Employees

89

Officers

President, CEO & Executive Director
Dr. Jeffrey L. Stein Ph.D.
COO & Corporate Secretary
Mr. Shane M. Ward
Chief Medical Officer
Dr. Taylor Sandison M.D., M.P.H.
Founder & Chief Strategy Officer
Dr. Kevin M. Forrest Ph.D.
CFO & Principal Accounting Officer
Dr. Preetam Shah M.B.A., Ph.D.
Senior Vice President of People & Culture
Ms. Allison Lewis CCP, SPHR
Show More
Chief Scientific Officer
Dr. Leslie Tari Ph.D.
Senior VP of Translational Research & Development
Dr. Nicole Davarpanah J.D., M.D.
Chief Business Officer
Mr. Jim Beitel M.B.A.
Show Less

See Also

Discover More
What is the Intrinsic Value of one CDTX stock?

The intrinsic value of one CDTX stock under the Base Case scenario is 19.79 USD.

Is CDTX stock undervalued or overvalued?

Compared to the current market price of 13.9 USD, Cidara Therapeutics Inc is Undervalued by 30%.

Back to Top